AZ-WORLD-VIEW
17.3.2022 15:46:04 CET | Business Wire | Press release
World View , an expert in stratospheric exploration on a mission to help spaceflight participants rediscover Earth, today announces the debut of its spaceflight capsule prototype. The announcement marks another exciting milestone for the company, following recent news of its entry into the space tourism sector and appointment of President of Tourism and Exploration, Dale Hipsh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005669/en/
Spaceflight participants eagerly awaiting the launch of commercial flights beginning in 2024 are provided a first-look at the distinctive World View experience, from onboard amenities and design touches to the superior hospitality and life-changing perspectives enjoyed throughout the journey.
“Unveiling our space capsule prototype is a pivotal moment for the company as we continue to prepare for our first launch from the Grand Canyon in just two short years,” said Ryan Hartman, President and Chief Executive Officer of World View. “We are thrilled to partner with leaders in aerospace design and engineering to bring our vision to life and ensure spaceflight participants enjoy a truly transformative experience.”
The exterior of the World View space capsule is shaped like a faceted hexagon with softened edges and a pearlescent white finish, which offers thermal management properties but also enhances the geometric detailing and curves. It boasts large elliptical windows that measure approximately 6.5 feet wide x 4.5 feet high, framing impressive views of the Earth’s curvature and its natural wonders. When seats are in a reclined position, the sky window on top of the capsule provides passengers an exciting line of sight to the balloon lifting them as well as constellations upon reaching float altitude. The central ceiling pelmet also includes a mood wash light that changes in accordance with the stage in flight to provide optimal viewing out of the capsule’s windows.
The capsule is climate-controlled and pressurized with an entire interior designed to maximize space, allowing spaceflight participants to move freely and comfortably about the capsule. The color palette, materials and finishes create an environment of calm, with clean lines, soft tones and clever concealment of functional elements–such as lavatory and galley entrances–so the focus remains on the stunning vistas and sights outside. Aligned with World View’s commitment to sustainability, great care is being taken to ensure materials are sourced from sustainable vendors whenever possible and options for re-use or recycling are being thoroughly explored.
Luxurious, ergonomic seating for eight passengers is configured in pairs, with an additional pair designated for crew members. Amenities including a cocktail table, graphical user interface (GUI) screen (providing educational materials and engaging activities), central console, personal storage and beverage holder, are at spaceflight participants’ fingertips to ensure that no moment of the journey is missed. Each capsule is outfitted with an onboard telescope to maximize viewing throughout the journey. Spaceflight participants will also enjoy gourmet custom dining options and top-shelf libations throughout their flight and each capsule will be equipped with streaming and mobile communication capabilities to stay in touch with loved ones back on Earth.
Projected lift off is scheduled before dawn, providing participants a front row seat to the sunrise on most flights. Along the journey, passengers will take in the curvature of the Earth, thin blue line of the atmosphere, vast darkness of space and constellations. Without the typical turbulence found on an airplane flight, spaceflight participants will be able to stand and move about the craft shortly after launch. The onboard crew, including one pilot and one concierge, serve as both Earth and space guides, cross-trained in flight operations, hospitality and medical support.
World View’s space tourism program begins launching commercial flights in 2024 with voyages taking off from natural and man-made wonders such as the Grand Canyon and Great Barrier Reef. Flights will lift passengers in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles above Earth, for an unparalleled experience that will last six to eight hours. Participants will fully experience and immerse themselves in the beauty, fragility, history and importance of the areas surrounding each location and of the Earth itself.
Design elements and engineering considerations continue to be refined. Further information on World View available at worldview.space .
ABOUT WORLD VIEW
World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005669/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
